These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
416 related articles for article (PubMed ID: 11309365)
1. Inducible expression of mutant alpha-synuclein decreases proteasome activity and increases sensitivity to mitochondria-dependent apoptosis. Tanaka Y; Engelender S; Igarashi S; Rao RK; Wanner T; Tanzi RE; Sawa A; L Dawson V; Dawson TM; Ross CA Hum Mol Genet; 2001 Apr; 10(9):919-26. PubMed ID: 11309365 [TBL] [Abstract][Full Text] [Related]
2. Expression of A53T mutant but not wild-type alpha-synuclein in PC12 cells induces alterations of the ubiquitin-dependent degradation system, loss of dopamine release, and autophagic cell death. Stefanis L; Larsen KE; Rideout HJ; Sulzer D; Greene LA J Neurosci; 2001 Dec; 21(24):9549-60. PubMed ID: 11739566 [TBL] [Abstract][Full Text] [Related]
3. Parkin protects against the toxicity associated with mutant alpha-synuclein: proteasome dysfunction selectively affects catecholaminergic neurons. Petrucelli L; O'Farrell C; Lockhart PJ; Baptista M; Kehoe K; Vink L; Choi P; Wolozin B; Farrer M; Hardy J; Cookson MR Neuron; 2002 Dec; 36(6):1007-19. PubMed ID: 12495618 [TBL] [Abstract][Full Text] [Related]
4. Endoplasmic reticulum stress and mitochondrial cell death pathways mediate A53T mutant alpha-synuclein-induced toxicity. Smith WW; Jiang H; Pei Z; Tanaka Y; Morita H; Sawa A; Dawson VL; Dawson TM; Ross CA Hum Mol Genet; 2005 Dec; 14(24):3801-11. PubMed ID: 16239241 [TBL] [Abstract][Full Text] [Related]
5. Proteasome mediates dopaminergic neuronal degeneration, and its inhibition causes alpha-synuclein inclusions. Sawada H; Kohno R; Kihara T; Izumi Y; Sakka N; Ibi M; Nakanishi M; Nakamizo T; Yamakawa K; Shibasaki H; Yamamoto N; Akaike A; Inden M; Kitamura Y; Taniguchi T; Shimohama S J Biol Chem; 2004 Mar; 279(11):10710-9. PubMed ID: 14672949 [TBL] [Abstract][Full Text] [Related]
6. [Parkinson's disease: what have we learned from the genes responsible for familial forms?]. Corti O; Brice A Med Sci (Paris); 2003 May; 19(5):613-9. PubMed ID: 12836396 [TBL] [Abstract][Full Text] [Related]
7. Expression of mutant alpha-synucleins enhances dopamine transporter-mediated MPP+ toxicity in vitro. Lehmensiek V; Tan EM; Schwarz J; Storch A Neuroreport; 2002 Jul; 13(10):1279-83. PubMed ID: 12151787 [TBL] [Abstract][Full Text] [Related]
8. Proteasomal inhibition leads to formation of ubiquitin/alpha-synuclein-immunoreactive inclusions in PC12 cells. Rideout HJ; Larsen KE; Sulzer D; Stefanis L J Neurochem; 2001 Aug; 78(4):899-908. PubMed ID: 11520910 [TBL] [Abstract][Full Text] [Related]
9. [Parkin, alpha-synuclein and other molecular aspects of Parkinson's disease]. Corti O; Brice A J Soc Biol; 2002; 196(1):95-10. PubMed ID: 12134640 [TBL] [Abstract][Full Text] [Related]
10. UCH-L1 aggresome formation in response to proteasome impairment indicates a role in inclusion formation in Parkinson's disease. Ardley HC; Scott GB; Rose SA; Tan NG; Robinson PA J Neurochem; 2004 Jul; 90(2):379-91. PubMed ID: 15228595 [TBL] [Abstract][Full Text] [Related]
11. Synphilin-1 degradation by the ubiquitin-proteasome pathway and effects on cell survival. Lee G; Junn E; Tanaka M; Kim YM; Mouradian MM J Neurochem; 2002 Oct; 83(2):346-52. PubMed ID: 12423244 [TBL] [Abstract][Full Text] [Related]
12. Alpha-Synuclein is degraded by both autophagy and the proteasome. Webb JL; Ravikumar B; Atkins J; Skepper JN; Rubinsztein DC J Biol Chem; 2003 Jul; 278(27):25009-13. PubMed ID: 12719433 [TBL] [Abstract][Full Text] [Related]
13. 6-Hydroxydopamine increases ubiquitin-conjugates and protein degradation: implications for the pathogenesis of Parkinson's disease. Elkon H; Melamed E; Offen D Cell Mol Neurobiol; 2001 Dec; 21(6):771-81. PubMed ID: 12043847 [TBL] [Abstract][Full Text] [Related]
14. Identification and functional characterization of a novel R621C mutation in the synphilin-1 gene in Parkinson's disease. Marx FP; Holzmann C; Strauss KM; Li L; Eberhardt O; Gerhardt E; Cookson MR; Hernandez D; Farrer MJ; Kachergus J; Engelender S; Ross CA; Berger K; Schöls L; Schulz JB; Riess O; Krüger R Hum Mol Genet; 2003 Jun; 12(11):1223-31. PubMed ID: 12761037 [TBL] [Abstract][Full Text] [Related]
15. Proteasome inhibition and aggregation in Parkinson's disease: a comparative study in untransfected and transfected cells. Biasini E; Fioriti L; Ceglia I; Invernizzi R; Bertoli A; Chiesa R; Forloni G J Neurochem; 2004 Feb; 88(3):545-53. PubMed ID: 14720204 [TBL] [Abstract][Full Text] [Related]
16. Alpha-synuclein and the Parkinson's disease-related mutant Ala53Thr-alpha-synuclein do not undergo proteasomal degradation in HEK293 and neuronal cells. Ancolio K; Alves da Costa C; Uéda K; Checler F Neurosci Lett; 2000 May; 285(2):79-82. PubMed ID: 10793231 [TBL] [Abstract][Full Text] [Related]
17. Proteolytic stress: a unifying concept for the etiopathogenesis of Parkinson's disease. McNaught KS; Olanow CW Ann Neurol; 2003; 53 Suppl 3():S73-84; discussion S84-6. PubMed ID: 12666100 [TBL] [Abstract][Full Text] [Related]
18. Wild-type but not Parkinson's disease-related ala-53 --> Thr mutant alpha -synuclein protects neuronal cells from apoptotic stimuli. da Costa CA; Ancolio K; Checler F J Biol Chem; 2000 Aug; 275(31):24065-9. PubMed ID: 10818098 [TBL] [Abstract][Full Text] [Related]